March 19, 2018

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG-BR003: Reminder! Amendment #1 was activated on March 7, 2018.

RTOG 1119: Amendments 8 and 9 have been approved by Health Canada.  Sites in Canada can access the NOL and TPD forms on CTSU.

1. Children’s Oncology Group Protocol AGCT1531: “A Phase III Trial of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors” is open to patient entry. It is available on the CTSU menu with Dr. Allan Covens as NRG Champion. Please enroll your eligible patients to this important trial.
Enrollment credited to NRG Oncology will count towards membership requirements.

NRG-GI004/SWOG S1610: Updated* Pathology, Correlative Science, and Imaging Submission Instructions, dated March 6, 2018 (posted on CTSU).
*Bioclinica information was updated in Section 4.

RTOG 1308:The Spanish-translated consent form is available on the CIRB documents tab on CTSU.

The VTOC Webinar Training Series schedule and registration are available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat. The next webinar training is scheduled for April 11, 2018.

Safety updates have been issued for NSABP legacy studies. For details, please see the NSABP E-mail Distributions page and CTSU.

Safety updates have been issued for the following studies:
- Atezolimumab: NRG-GI004, NRG-GY009
- Ipilimumab: NRG-BN002, NRG-GY003
- Nivolumab: NRG-BN002, NRG-GY002, NRG-GY003
- Trametinib: GOG-0281 

  • For GOG-0281, NRG-GI004, and NRG-GY009 safety reports, please see CTSU.
  • For NRG-GY002 and NRG-GY003 safety reports, please see the protocol page on NRG Oncology.
  • For NRG-BN002 safety reports, please see the RTOG General Broadcast page.

 An Investigator’s Brochure notice has been issued for the following studies:

- Olaparib: NRG-GY004, NRG-GY005

The current version of the Investigator Brochure Documents (IB-Summary of Changes) for Olaparib (AZD2281) NSC 747856 for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Online Agent Order Processing (OAOP) website ( Log-in using your Identity and Access Management (IAM) username and password credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

Reminder: Deadline Approaching
The NRG Oncology Cancer Care Delivery Research (CCDR) Committee is Accepting Applications
The NRG Oncology Cancer Care Delivery Research (CCDR) Committee is currently accepting applications for membership. Please be sure to read the application form for details regarding the application process and committee member responsibility.

If you are interested in becoming a member of the CCDR Committee, please complete the application and return the form and necessary materials by Friday, March 30, 2018.

Please forward questions to: 
Click here to download form and instructions

Please click here to participate in a brief survey regarding our NRG Oncology website protocol table. We would love to hear your opinions and any suggestions you may have to improve your experience.

Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings
American Association for Cancer Research (AACR); Apr 14-18, 2018; Chicago, IL
American Head & Neck Society (AHNS); Apr 18-19, 2018; National Harbor, MD
European Society for Radiotherapy and Oncology (ESTRO); Apr 20-24, 2018; Barcelona, Spain
Society of Gynecologic Oncology (SGO); Mar 24-27, 2018; New Orleans, LA
Society of Surgical Oncology (SSO); Mar 21-24, 2018; Chicago, IL

Upcoming Abstract Submission Deadlines
American Society for Radiation Oncology (ASTRO); Oct 21-24, 2018; San Diego, CA; Late-breaking Aug 1, 2018
European Society for Medical Oncology (ESMO); Oct 19-23, 2018;Munich, Germany; due to publications committee Apr 25, 2018; meeting abstracts submission deadline May 9, 2018; Late-breaking Sep 17, 2018
International Society for Quality of Life Research (ISOQOL); Oct 24-27, 2018; Dublin, Ireland; due to publications committee Apr 2, 2018; meeting abstracts submission deadline Apr 16, 2018
Multinational Association of Supportive Care in Cancer (MASCC); Jun 28-30, 2018; Vienna, Austria; Late-breaking due Apr 22, 2018
Radiological Society of North America (RSNA); Nov 25-30, 2018; Chicago, IL; due to publications committee Mar 28, 2018; meeting abstracts submission deadline Apr 11, 2018
Western Association of Gynecologic Oncologists (WAGO); Jun 13-16, 2018; Park City, UT; due to publications committee Mar 19, 2018; meeting abstracts submission deadline Apr 2, 2018

Do you have feedback on how we can improve our weekly email broadcasts? Please send any suggestions or ideas to

NRG Oncology is proud to be an active participant of #CancerMoonShot.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103

Update Profile/Email Address